

04:05 PM 22 DEC MARKET STATS ▾	SENSEX 25,980 ▼ -262.78	NIFTY 50 7,979 ▼ -82.20	GOLD (MCX) (Rs/10g.) 26,944 ▼ -46.00	USD/INR 67.99 ▲ 0.08	CREATE PORTFOLIO	Download ET MARKETS APP Apple Android	CHOOSE LANGUAGE ENG	LIVE TV
--	-----------------------------------	-----------------------------------	--	--------------------------------	------------------	--	------------------------	---------

Sun Pharma, Moebius Medical to develop osteoarthritis pain product

By ET Bureau | Updated: Dec 12, 2016, 05:33 PM IST

[Post a Comment](#)

MUMBAI: [Sun Pharma](#) and Israel-based [Moebius Medical](#) have entered into an exclusive worldwide licensing deal to further develop MM-II, a novel pharmaceutical candidate for the treatment of pain in [osteoarthritis](#), Sun said in a release to the press.

MM-II is an intra-articular bio lubricant injection which is being developed to provide symptomatic relief of mild-to-moderate [osteoarthritis pain](#). The product is based on patent-protected technology licensed by Moebius Medical from the Hebrew University of Jerusalem, Technion Israel Institute of Technology and Hadassah Medical Centre.

Sun pharma said initial clinical data showed superior efficacy and similar safety of MM-II vs the standard case which is hyaluronic acid for treatment of pain in osteoarthritis. Sun will be funding the clinical development of the molecule and will possess the worldwide commercialisation and manufacturing rights. MM-II is a novel non-opioid product, Sun said that leverages the physical properties of proprietary liposomes to lubricate arthritic knee joints, thereby reducing friction and wear, consequently leading to joint pain reduction.

Moebius Medical so far has completed a first-in-man clinical study at Hadassah Medical Center, Moebius Medical will conduct requisite pre-clinical studies, and will assume responsibility for product development and manufacturing through the end of Phase-II studies. Sun Pharma will assume responsibility for further clinical studies, regulatory submissions and product commercialization. Moebius Medical will receive an upfront payment, development-based and sales-based milestone payments, and tiered royalties on sales from Sun Pharma.

Stay on top of business news with The Economic Times App. [Download it Now!](#)

RELATED COMPANIES EXPAND

[Sun Pharma](#) SLIDE SHOW

THE ECONOMIC TIMES

Live Market	News	Portfolio	Mobile	Live TV	Newsletter	Commodities	Speed	QnA	Blogs	Alerts	RSS
Other Times Group news sites Times of India इकनॉमिक टाइम्स छंदीनीमिड टाइम्स Mumbai Mirror Times Now Indiatimes नवभारत टाइम्स महाराष्ट्र टाइम्स ವಿಜಯ ಕರ್ನಾಟಕ Lifehacker Gizmodo Eisamay IGN India NavGujarat Samay	Living and entertainment Timescity iDiva Zoom Luxpresso Gaana Happytrips Cricbuzz Get Smartapp Networking itimes MensXP.com	Hot on the Web Budget 2017 Sensex, Nifty Live Year-End Special 2016 UP & Punjab Assembly Elections 2017 Live: Currency Demonetisation Gold Rate RBI Monetary Policy	Services ads2book Gadgetsnow Free Business Listings Simplymarry Astrospeak Timesjobs Magicbricks Zigwheels Timesdeal dineout Filmipop Remit2India Gaana Greetzap Techradar Alivear Google Play								